Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

Item

http://www.wikidata.org/entity/Q36536280

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@ast

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@en

type

Item

label

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@ast

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@en

prefLabel

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@ast

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@en

P1476

Prolonged-release nicotinic ac ...... esults from the NAUTILUS study

@en

P2093

Anja Vogt

http://www.w3.org/2001/XMLSchema#string

Ulrike Hostalek

http://www.w3.org/2001/XMLSchema#string

Ursula Kassner

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.

Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

Clinical review 124: Diabetic dyslipidemia: causes and consequences.

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

P304

467-479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/VHRM.S1023

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elisabeth Steinhagen-Thiessen

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17969377

http://www.w3.org/2001/XMLSchema#string

P921

lipid metabolism disorder

mechanism of action

dyslipidemias

P932

2291331

http://www.w3.org/2001/XMLSchema#string